Two decades of biologic and JAK inhibitor prescription patterns in the western region of Melbourne

Documenti analoghi

• The cardiovascular risk of JAK inhibitors in treating rheumatic diseases
  di: Alexander Kwan, et al.
  Pubblicazione: (2024)
• Clinical outcomes of hepatocellular carcinoma surveillance in Melbourne, Australia
  di: Samuel Hui, et al.
  Pubblicazione: (2024)
• Two decades at the helm: it only seems like a few weeks
  di: Jeff Szer
  Pubblicazione: (2025)
• Clinical risk factors and antimicrobial resistance associated with campylobacteriosis in Melbourne, Australia: a retrospective analysis
  di: Arvind Yerramilli, et al.
  Pubblicazione: (2026)
• Use of sodium–glucose cotransporter‐2 inhibitors among Aboriginal people with type 2 diabetes in remote Northern Territory: 2012 to 2020
  di: Matthew J. L. Hare, et al.
  Pubblicazione: (2025)